The FDA’s fiscal year 2027 A-list prioritises final guidance on AI-enabled device software and robotically assisted surgical devices, alongside a draft on conversational AI for mental disorders. These are intended publication priorities, not final documents or device approvals. FDA priority list; what the lists mean
The list separates work intended for final publication from topics where the next step would be a draft. That distinction matters when tracking what manufacturers can expect next.
Which technology topics are on the list?
The table selects technology-related items from the FDA’s two-page plan; it is not the complete guidance programme.
| Topic | FY2027 placement | Planned document stage |
|---|---|---|
| AI device software lifecycle and marketing submissions | A-list | Final guidance |
| Robotically assisted surgical devices | A-list | Final guidance |
| Generative AI conversational devices for mental disorders | A-list | Draft guidance |
| Pulse oximeters for medical purposes | B-list | Final guidance |
| Postmarket cybersecurity management | B-list | Draft guidance |
The FDA’s explanation of the lists describes the A-list as its intended annual priorities. B-list documents depend on resources. Neither list guarantees publication: urgent work, submission reviews and changing priorities can alter the programme.
Two existing drafts remain proposals
The current AI lifecycle guidance page still identifies the January 2025 document as draft and not for implementation. It describes proposed information for marketing submissions, together with recommendations on device design and development across the product’s lifecycle. Being listed for finalisation does not itself turn that draft into final guidance.
The surgical-device guidance page likewise remains draft. It covers proposed non-clinical testing, clinical data and labelling for certain robotically assisted surgical devices. The systems described are teleoperated: qualified practitioners control surgical instruments through software-controlled equipment. The document’s scope should not be conflated with fully autonomous surgery.
The surgical draft’s page gives 24 November 2026 as the date for comments to be considered before work begins on the final version. The FDA also notes that comments on guidance may be submitted at any time.
What to watch for next
For the two existing drafts, the relevant next event is publication of a final document, with its actual wording and scope. For the conversational-AI topic, the planned next stage is a draft open to scrutiny. The priority list supplies neither a product approval nor evidence that a particular device is safe or effective.